Close Menu

Chlamydia trachomatis

The GenFlex is a sample-to-result molecular diagnostic platform that includes sample collection, processing, amplification, and detection, the company said.

The Ithaca, New York-based firm has submitted its molecular diagnostic instrument along with a test to detect chlamydia, gonorrhea, and trichomonas.

The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.

Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.

The Ann Arbor, Michigan-based firm will compete with a few well-established players offering systems that can run in vitro diagnostic tests as well as lab-developed tests. 

The firm said that its Cobas CT/NG real-time PCR assay is the first available in the US for the testing of sexually transmitted infections on its 6800 and 8800 systems.

The company said it will use the funds to expand its menu of STI tests and launch its io rapid diagnostic platform into UK sexual health clinics.

In Genome Research this week: population genomics and genome dynamics of Chlamydia, non-coding mutation found in microcephaly-micromelia syndrome, and more.

The funding comes from a syndicate which includes all Series C investors and one new investor, Chinese assay developer Wondfo Biotech.

Sequences from Chlamydia trachomatis strains in northern Australia suggest trachoma infections in the eye may be caused by small changes to urogenital strains.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.